ArticleClinical ophthalmology (Auckland, N.Z.)2025
Tailored Anti-VEGF Therapy with New Generation Optimizations (TANGO) Treatment Regimen for Neovascular Age-Related Macular Degeneration: Rationale, Design, and Simulation Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Durability of Three Monthly Loading Doses with Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration.Ophthalmology and therapy · 2026Article
- Efficacy and Safety of Intravitreal Faricimab in Age-Related Macular Degeneration-A Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To present the rationale and design of the Tailored Anti-VEGF therapy with New Generation Optimizations (TANGO) treatment regimen for neovascular age-related macular degeneration and to simulate potential number of visits and injections with TANGO and compare to other treatment regimens. Methods: This is a descriptive short report of the rationale and design of TANGO. The purpose of TANGO is to lessen the burden of therapy with new generation anti-VEGF medications that have better durability. We also simulate the potential number of visits and injections during the first year with TANGO and compare these numbers to other treatment regimens. Results: Our report describes TANGO and provides a flow chart for its use. Our simulations suggest that TANGO may lead to a reduced number of visits and injections. Conclusion: Our simulations suggest that employing TANGO may lead to a reduced number of visits and anti-VEGF injections while still providing intensive therapy for those who require it. However, it should be emphasized that this is a descriptive report and a simulation study, and clinical real-world studies of efficacy and safety using TANGO are warranted to better understand implications of employing TANGO in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.